๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus

โœ Scribed by Burt, R K; Marmont, A; Arnold, R; Heipe, F; Firestein, G S; Carrier, E; Hahn, B; Barr, W; Oyama, Y; Snowden, J

Book ID
110013649
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
95 KB
Volume
32
Category
Article
ISSN
0007-1188

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Efficacy and safety of rituximab in mode
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
โœ Joan T. Merrill; C. Michael Neuwelt; Daniel J. Wallace; Joseph C. Shanahan; Kevi ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 499 KB ๐Ÿ‘ 2 views

## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p

B cell depletion as a novel treatment fo
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
โœ R. John Looney; Jennifer H. Anolik; Debbie Campbell; Raymond E. Felgar; Faith Yo ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 199 KB

## Abstract ## Objective Safer and more effective therapies are needed for the treatment of systemic lupus erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for